Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Related Citations for PubMed (Select 22041180)

1.

Etanercept in spondyloarthropathies. Part I: current evidence of efficacy.

Palazzi C, D'Angelo S, Cantini F, Lubrano E, Marchesoni A, Mathieu A, Salvarani C, Scarpa R, Spadaro A, Olivieri I.

Clin Exp Rheumatol. 2011 Sep-Oct;29(5):858-64. Epub 2011 Oct 31. Review.

PMID:
22041180
2.

Biologic therapies in the spondyloarthritis: new opportunities, new challenges.

Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J.

Curr Opin Rheumatol. 2003 Jul;15(4):394-407. Review.

PMID:
12819466
3.
4.
5.

Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation.

Wade AG, Crawford GM, Pumford N, Koscielny V, Maycock S, McConnachie A.

BMC Med Res Methodol. 2011 Jun 14;11:91. doi: 10.1186/1471-2288-11-91.

6.

[Spondylarthropathies and anti-TNFalpha drugs].

Pavy S, Allanore Y, Kahan A.

Rev Med Interne. 2005 Sep;26(9):717-24. Epub 2005 Mar 17. Review. French.

PMID:
16154026
7.

[Anti-TNF-alpha treatment and spondyloarthropathies].

Braun Y, Balbir-Gurman A.

Harefuah. 2002 Nov;141(11):965-8, 1010. Hebrew.

PMID:
12476631
9.

Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.

Maksymowych WP, Inman RD, Gladman D, Thomson G, Stone M, Karsh J, Russell AS; Spondyloarthritis Research Consortium of Canada (SPARCC).

J Rheumatol. 2003 Jun;30(6):1356-63. Review.

PMID:
12784417
10.

Juvenile spondyloarthropathies and related arthritis.

Bukulmez H, Colbert RA.

Curr Opin Rheumatol. 2002 Sep;14(5):531-5. Review.

PMID:
12192250
11.
12.

Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor alpha blockade.

Paul S, Keat A.

Rheumatology (Oxford). 2005 Jan;44(1):17-23. Epub 2004 Aug 24. Review. No abstract available.

13.

Anti-tumour necrosis factor (TNF)-alpha therapy in undifferentiated spondyloarthropathy.

Schnarr S, Kuipers JG, Zeidler H.

Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S126-9. Review.

PMID:
12463462
14.

[Therapeutic use of anti-TNF-alpha agents in spondyloarthropathies].

Wendling D, Claudepierre P, Lohse A, Toussirot E, Breban M.

Presse Med. 2003 Oct 4;32(32):1517-24. Review. French.

PMID:
14534471
15.

Etanercept treatment in resistant spondyloarthropathy: imaging, duration of effect and efficacy on reintroduction.

Marzo-Ortega H, McGonagle D, Emery P.

Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S175-7.

PMID:
12463472
16.

Anti-TNF-alpha therapy for ankylosing spondylitis--a specific or nonspecific treatment?

Dayer JM, Krane SM.

N Engl J Med. 2002 May 2;346(18):1399-400. No abstract available.

PMID:
11986415
17.

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W; Enbrel Ankylosing Spondylitis Study Group.

Arthritis Rheum. 2003 Nov;48(11):3230-6.

18.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

19.

Prolonged efficacy of etanercept in refractory enthesitis-related arthritis.

Henrickson M, Reiff A.

J Rheumatol. 2004 Oct;31(10):2055-61.

PMID:
15468375
20.

Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept.

Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.

J Rheumatol. 2004 Mar;31(3):531-8.

PMID:
14994401
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk